Limits...
In contrast to matrix metalloproteinases, serum adiponectin concentrations increase after radioiodine treatment of thyrotoxicosis.

Lewiński A, Brona A, Lewandowski K, Skowrońska-Jóźwiak E, Milewicz A - Thyroid Res (2012)

Bottom Line: Matrix metalloproteinases (MMPs), together with their tissue inhibitors (TIMPs), remodel extracellular matrix under physiological and pathological conditions and are implicated in pathogenesis of cardiovascular diseases, cancer and in chronic inflammation.There was no significant change MMP-2, MMP-9 and TIMP-1 between V1 and V3.There was a decrease in FT4 and FT3 from 24.4±15.4 pmol/l (V1) to 14.7±10.6 pmol/l (V3), and from 10.0±5.65 (V1) to 6.1±4.8 pmol/l (V2), p<0.01, for FT4 and FT3, respectively.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Endocrinology and Metabolic Diseases, Medical University of Lodz, Rzgowska St, No, 281/289, 93-338 Lodz, Poland. alewin@csk.umed.lodz.pl.

ABSTRACT

Background: Matrix metalloproteinases (MMPs), together with their tissue inhibitors (TIMPs), remodel extracellular matrix under physiological and pathological conditions and are implicated in pathogenesis of cardiovascular diseases, cancer and in chronic inflammation. We have endeavoured to assess whether concentrations of MMPs, TIMPs, and anti-inflammatory adiponectin are altered by pharmacological treatment of acute thyrotoxicosis or by radioiodine therapy (RIT).

Material and methods: We measured serum concentrations of MMP-2, MMP-9, TIMP-1, TIMP-2, and adiponectin, TSH, free T4 (FT4) and free T3 (FT3) in 15 patients (4 males), age (years) 51.8±15.3 (mean±SD) with hyperthyroidism treated with thiamazole (Group 1) and in 20 subjects (2 males), treated for thyrotoxicosis with radioiodine, age 52.3±12.4 (Group 2), where blood samples were taken before RIT, visit 1 (V1), seven days post RIT, visit 2 (V2), and two to three months post RIT, visit 3 (V3).

Results: In Group 1 there was no significant change in concentrations of MMP-2, MMP-9, TIMP-1, TIMP-2 or adiponectin, despite a fall in FT4 and FT3 (8.74±4.79 pg/ml vs 3.54±2.40 pg/ml, for FT3, and 4.48 ±2.21 ng/ml vs 1.02±1.07 ng/ml, for FT4, p<0.001). In Group 2 RIT did not cause any acute change in serum MMP-2, MMP-9, TIMP-1 and TIMP-2 or adiponectin (V1 vs V2). However, there was a significant increase in serum adiponectin [from 15201±8860 ng/ml (V1) to 19373±8657 ng/ml (at V3), p<0.05], and TIMP-2 at V3 [from 129±45 ng/ml (V1) to 149±38 ng/ml (V3), p<0.01]. There was no significant change MMP-2, MMP-9 and TIMP-1 between V1 and V3. There was a decrease in FT4 and FT3 from 24.4±15.4 pmol/l (V1) to 14.7±10.6 pmol/l (V3), and from 10.0±5.65 (V1) to 6.1±4.8 pmol/l (V2), p<0.01, for FT4 and FT3, respectively.

Conclusions: Radioiodine therapy of thyrotoxicosis does not alter serum MMP-2, MMP-9 or TIMP-1 concentrations either acutely or after about three months of observation. An increase in serum adiponectin might reflect favourable effects of radioiodine administration on cardiovascular risk factors, while an increase in TIMP-2 (principal MMP-2 inhibitor) might lead to a decrease in free MMP-2 concentrations.

No MeSH data available.


Related in: MedlinePlus

Mean MMP-2/TIMP2 ratio and standard deviations in subjects treated with radioactive iodine, i.e., before radioiodine therapy (RIT), visit 1 (V1), seven days post RIT, visit 2 (V2), and two-three months post RIT, visit 3 (V3). Statistical significance is marked by “*” (V1 vs V2, p<0.05), and by “**” (V1 vs V3, p<0.01).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3526470&req=5

Figure 2: Mean MMP-2/TIMP2 ratio and standard deviations in subjects treated with radioactive iodine, i.e., before radioiodine therapy (RIT), visit 1 (V1), seven days post RIT, visit 2 (V2), and two-three months post RIT, visit 3 (V3). Statistical significance is marked by “*” (V1 vs V2, p<0.05), and by “**” (V1 vs V3, p<0.01).

Mentions: Results of the study are presented in Tables 1,2,3.4, Figure 1 and Figure 2. As expected, in patients from Group 1, there was a marked fall in FT4 and FT3. There was, however, no significant change in concentrations of MMP-2, MMP-9, TIMP-1, TIMP-2 and adiponectin (Table 1).


In contrast to matrix metalloproteinases, serum adiponectin concentrations increase after radioiodine treatment of thyrotoxicosis.

Lewiński A, Brona A, Lewandowski K, Skowrońska-Jóźwiak E, Milewicz A - Thyroid Res (2012)

Mean MMP-2/TIMP2 ratio and standard deviations in subjects treated with radioactive iodine, i.e., before radioiodine therapy (RIT), visit 1 (V1), seven days post RIT, visit 2 (V2), and two-three months post RIT, visit 3 (V3). Statistical significance is marked by “*” (V1 vs V2, p<0.05), and by “**” (V1 vs V3, p<0.01).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3526470&req=5

Figure 2: Mean MMP-2/TIMP2 ratio and standard deviations in subjects treated with radioactive iodine, i.e., before radioiodine therapy (RIT), visit 1 (V1), seven days post RIT, visit 2 (V2), and two-three months post RIT, visit 3 (V3). Statistical significance is marked by “*” (V1 vs V2, p<0.05), and by “**” (V1 vs V3, p<0.01).
Mentions: Results of the study are presented in Tables 1,2,3.4, Figure 1 and Figure 2. As expected, in patients from Group 1, there was a marked fall in FT4 and FT3. There was, however, no significant change in concentrations of MMP-2, MMP-9, TIMP-1, TIMP-2 and adiponectin (Table 1).

Bottom Line: Matrix metalloproteinases (MMPs), together with their tissue inhibitors (TIMPs), remodel extracellular matrix under physiological and pathological conditions and are implicated in pathogenesis of cardiovascular diseases, cancer and in chronic inflammation.There was no significant change MMP-2, MMP-9 and TIMP-1 between V1 and V3.There was a decrease in FT4 and FT3 from 24.4±15.4 pmol/l (V1) to 14.7±10.6 pmol/l (V3), and from 10.0±5.65 (V1) to 6.1±4.8 pmol/l (V2), p<0.01, for FT4 and FT3, respectively.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Endocrinology and Metabolic Diseases, Medical University of Lodz, Rzgowska St, No, 281/289, 93-338 Lodz, Poland. alewin@csk.umed.lodz.pl.

ABSTRACT

Background: Matrix metalloproteinases (MMPs), together with their tissue inhibitors (TIMPs), remodel extracellular matrix under physiological and pathological conditions and are implicated in pathogenesis of cardiovascular diseases, cancer and in chronic inflammation. We have endeavoured to assess whether concentrations of MMPs, TIMPs, and anti-inflammatory adiponectin are altered by pharmacological treatment of acute thyrotoxicosis or by radioiodine therapy (RIT).

Material and methods: We measured serum concentrations of MMP-2, MMP-9, TIMP-1, TIMP-2, and adiponectin, TSH, free T4 (FT4) and free T3 (FT3) in 15 patients (4 males), age (years) 51.8±15.3 (mean±SD) with hyperthyroidism treated with thiamazole (Group 1) and in 20 subjects (2 males), treated for thyrotoxicosis with radioiodine, age 52.3±12.4 (Group 2), where blood samples were taken before RIT, visit 1 (V1), seven days post RIT, visit 2 (V2), and two to three months post RIT, visit 3 (V3).

Results: In Group 1 there was no significant change in concentrations of MMP-2, MMP-9, TIMP-1, TIMP-2 or adiponectin, despite a fall in FT4 and FT3 (8.74±4.79 pg/ml vs 3.54±2.40 pg/ml, for FT3, and 4.48 ±2.21 ng/ml vs 1.02±1.07 ng/ml, for FT4, p<0.001). In Group 2 RIT did not cause any acute change in serum MMP-2, MMP-9, TIMP-1 and TIMP-2 or adiponectin (V1 vs V2). However, there was a significant increase in serum adiponectin [from 15201±8860 ng/ml (V1) to 19373±8657 ng/ml (at V3), p<0.05], and TIMP-2 at V3 [from 129±45 ng/ml (V1) to 149±38 ng/ml (V3), p<0.01]. There was no significant change MMP-2, MMP-9 and TIMP-1 between V1 and V3. There was a decrease in FT4 and FT3 from 24.4±15.4 pmol/l (V1) to 14.7±10.6 pmol/l (V3), and from 10.0±5.65 (V1) to 6.1±4.8 pmol/l (V2), p<0.01, for FT4 and FT3, respectively.

Conclusions: Radioiodine therapy of thyrotoxicosis does not alter serum MMP-2, MMP-9 or TIMP-1 concentrations either acutely or after about three months of observation. An increase in serum adiponectin might reflect favourable effects of radioiodine administration on cardiovascular risk factors, while an increase in TIMP-2 (principal MMP-2 inhibitor) might lead to a decrease in free MMP-2 concentrations.

No MeSH data available.


Related in: MedlinePlus